Back to search
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
Advanced or Metastatic Colorectal Cancer
Clinicaltrials.gov:
EU CTIS:
#2023-506517-22-00
EudraCT:
J&J ID:
#CR109215
Other:
#61186372GIC2002
Interested in this trial?
Subscribe or share this trial
Trials at a glance
Status
Enrolling
Condition
Advanced or Metastatic Colorectal Cancer
Trial type
Interventional
Trial phase
Phase 1
Investigational
product
product
Amivantamab
Amivantamab IV
Fluorouracil
Irinotecan
Leucovorin
Oxaliplatin
Age
18+ years old
Biological sex
All
Placebo?
No
Trial start date
July 29, 2022
Trial end date
October 31, 2030
CT.gov ID
#NCT05379595
Share the trial ID with your doctor to see if trial participation is right for you. Participation depends on an independent medical assessment.
Countries:
- Belgium,
- Canada,
- China,
- Germany,
- Italy,
- Malaysia,
- Puerto Rico,
- South Korea,
- Spain,
- Taiwan,
- United States
Loading...
Enrolling
Milan, Italy, 20162
Enrolling
Ponce, Puerto Rico, 00717
Enrolling
Seoul, South Korea, 05505
Enrolling
Hamburg, Germany, 22763
Enrolling
Pisa, Italy, 56126
Enrolling
Petaling Jaya, Malaysia, 46050
Enrolling
Changhua, Taiwan, 500
Enrolling
Liou Ying Township, Taiwan, 736
Enrolling
Brussels, Belgium, 1200
Enrolling
Milan, Italy, 20133
Enrolling
Hattiesburg, Mississippi, United States, 39401
Enrolling
New York, New York, United States, 10032
Enrolling
Madrid, Spain, 28040
Enrolling
Madrid, Spain, 28050
Enrolling
Barcelona, Spain, 08035
Enrolling
Valencia, Spain, 46010
Enrolling
Madrid, Spain, 28007
Enrolling
Santander, Spain, 39008
Enrolling
Madrid, Spain, 28034
Enrolling
Kuching, Malaysia, 93586
Enrolling
Wuhan, China, 430079
Enrolling
Anderlecht, Belgium, 1070
Enrolling
Kaohsiung City, Taiwan, 83301
Enrolling
Taoyuan, Taiwan, 33305
Enrolling
Munich, Germany, 81377
Enrolling
Houston, Texas, United States, 77030
Enrolling
New York, New York, United States, 10016
Enrolling
Tainan, Taiwan, 704
Enrolling
Taipei, Taiwan, 10002
Enrolling
Rio Piedras, Puerto Rico, 00935
Enrolling
Toronto, Ontario, Canada, M5G 1X6
Enrolling
Seoul, South Korea, 06351
Enrolling
Seoul, South Korea, 03080
Enrolling
Seoul, South Korea, 03722
Enrolling
Guangzhou, China, 510655
Enrolling
Seoul, South Korea, 06591
Enrolling
Ottawa, Ontario, Canada, K1H 8L6
Enrolling
Hangzhou, China, 310003
Enrolling
Edegem, Belgium, 2650
Enrolling
Leuven, Belgium, 3000
Enrolling
Kuala Lumpur, Malaysia, 59100
Enrolling
Los Angeles, California, United States, 90404
Enrolling
Ann Arbor, Michigan, United States, 48103
Enrolling
Nashville, Tennessee, United States, 37232
Enrollment complete
Oklahoma City, Oklahoma, United States, 73104
Completed
Vancouver, British Columbia, Canada, V5Z 4E6
Completed
Washington D.C., District of Columbia, United States, 20007
Completed
Tampa, Florida, United States, 33612
Completed
Birmingham, Alabama, United States, 35233
Completed
Grand Rapids, Michigan, United States, 49546
Completed
Dalian, China, 116023
Completed
Baltimore, Maryland, United States, 21201
Completed
Los Angeles, California, United States, 90033
#
More than 50 sites in this region
#
More than 10 sites in this region
#
Less than 10 sites in this region
Individual sites
Access detailed information on the trial:
Clinical trials information
© Johnson & Johnson and its affiliates 2026
